43 episodes

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

Cell & Gene: The Podcast Erin Harris

    • Science
    • 4.9 • 30 Ratings

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

    2023 Market Outlook with AdBio and ISCT's Miguel Forte

    2023 Market Outlook with AdBio and ISCT's Miguel Forte

    Miguel Forte is Entrepreneur in Residence at AdBio, a VC firm based in France, and President Elect of ISCT. Forte and Cell & Gene: The Podcast host, Erin Harris, break down market outlook perspective for the cell and gene therapy space. He provides valuable tips to employ when seeking VC partnership, and he covers ISCT's primary focus areas and what to expect from ISCT 2023 Paris.

    • 26 min
    CMC and Scale Up with Mustang Bio's Robert Sexton

    CMC and Scale Up with Mustang Bio's Robert Sexton

    MustangBio's Robert Sexton, VP Program and Alliance Leadership, explains the why behind the need for this role in any CGT company. Having worked for Novartis, Sanofi, Legend Biotech, and more, with responsibilities having included quality, operations, and order management, Sexton is currently responsible for aspects of CMC. As such, he addresses the industry's top CMC challenges as well as sound advice for future scale up.

    • 36 min
    An Interview with Dr. Peter Marks

    An Interview with Dr. Peter Marks

    Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with Cell & Gene: The Podcast host Erin Harris to discuss the most anticipated areas of innovation in clinical development, and he offers recommendations to companies in their engagement with the FDA in order to make manufacturing more streamlined and cost effective. Dr. Marks also provides advice to listeners about how and when to engage with CBER, and much more.

    • 28 min
    Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth

    Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth

    Shoreline Biosciences' Chief Scientific Officer Dr. Robert Hollingsworth shares his insight on intelligently designed allogeneic off-the-shelf, standardized, and targeted iPSC-derived natural killers (NK) and macrophage cellular immunotherapies. He explains the company's preclinical testing on a potential NK cell therapy for acute myeloid leukemia. We discuss how the field recognizes the importance of off-the-shelf NK cell therapy not only for cost reduction but also for improving safety measures. As such, Dr. Hollingsworth talks through why NK cells necessary to move immunotherapies forward.

    • 26 min
    The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg

    The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg

    BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.

    • 28 min
    Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan

    Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan

    Orgenesis' CEO, Vered Caplan explains the business model behind providing cell and gene therapies that may be manufactured at the point of care. She details how working with hospitals and healthcare providers to enable them to participate in CGT development on their sites and providing these therapies in-house by adapting them to closed system manufacturing rather than relying on the typical biotech model is an important step forward in CGT manufacturing. 

    • 36 min

Customer Reviews

4.9 out of 5
30 Ratings

30 Ratings

buck025 ,

Top Notch Podcast

I’ve learned a great deal listening to this podcast. Erin Harris does a fantastic job of keeping the topics current and the guests she has on are all leaders in the industry.

Derek VS ,

Must listen for anyone in this market

If you’re interested in what the leaders of the cell therapy and gene therapy market think, this is well worth a subscribe.

MoodyPooty ,

Required Listening

The cell and gene space is growing and developing quickly. The Cell and Gene Podcast is the best way to keep up with this exciting and quickly developing segment of the pharma industry.

Top Podcasts In Science

Hidden Brain
Alie Ward
Jeremy Corbell, George Knapp, Cadence13 and Dark Horse Entertainment
Neil deGrasse Tyson
Sam Harris
Blurry Creatures

You Might Also Like

Timmerman Report
STAT
Matt Pillar
Vincent Racaniello
Harvard Business Review
Springer Nature Limited